A Randomized Open Label Pilot Trial of a Biomarker Guided Strategy of Cardioprotection in Patients with Lymphoma or Breast Cancer Treated with Anthracyclines

You will be receiving anthracycline-based chemotherapy (Adriamycin/doxorubicin) as part of your cancer treatment plan. Although anthracycline-based chemotherapy is effective in treating cancer, it can damage your heart. This study has two goals. The first goal is to see if we can identify who is most at risk for this heart damage by measuring a hormone that is released into the blood when the heart is under stress (NT-proBNP). The second goal is to determine if we can prevent cardiac damage in participants with elevated levels of this hormone by starting treatment with widely used heart medications that are FDA approved to treated weakened heart function. The medicines will be prescribed in a way that is tailored to individual participants but will usually include a beta-blocker and an ACE inhibitor, medications commonly used to treat hypertension (high blood pressure) as well as weakened heart muscles

You may be eligible for this study if you meet the following criteria:

• Conditions: Lymphoma,Breast Cancer
• Age: 18 years - 99 years
• Gender: All